The Research On China Resources Group Acquisition Of Sanjiu Pharmaceutical Performance And Financial

In recent years, mergers and acquisitions have become an important way to the development of modern enterprises, the world's top-ranking companies, including most of the multinational pharmaceutical companies have carried out different sizes and levels of mergers and acquisitions. Foreign acquisitions have been a hundred years of history, while only a short twenty years, but with a speed of reform and opening up 30 years of economic development, China's mergers and acquisitions in the world who plays an increasingly important role, both domestic and foreign scholars on the success rate of mergers and acquisitions in the empirical study, the findings showed that the success rate is low acquisitions. There are many reasons, mainly because there is no effective integration of corporate acquisitions, mergers and acquisitions and financial integration is a very critical aspect of performance study of mergers and acquisitions in the financial consolidation of its financial extremely important. Pharmaceutical industry is always a sunrise industry, the pharmaceutical industry in recent years, M & A cases increased year by year, involving an amount of rising hot industry mergers and acquisitions took place. Currently the national introduction of policies to encourage pharmaceutical companies to become bigger and stronger through mergers and acquisitions, in the double support of national policies and market-oriented, the domestic pharmaceutical companies will accelerate the merger integration. Select this article Sanjiu Pharmaceutical Resources Group's acquisition of this case, to study the financial performance before and after the merger Sanjiu Pharmaceutical.Firstly, the theoretical basis for the merger and acquisition of financial performance related concepts are described in detail, including mergers and acquisitions of financial performance evaluation is selected, laid the theoretical foundation for later analysis. Then introduces the basic situation of China Resources Sanjiu Pharmaceutical Group's acquisition cases, and comparative analysis of the financial performance of Sanjiu Pharmaceutical acquisitions before and after using the individual financial indicators and overall financial performance evaluation system, including the DuPont analysis and economic value added (EVA) method on the financial performance of the overall evaluation of Sanjiu Pharmaceutical. Finally get inspiration to improve the financial performance of M & A by this case. In this paper, corporate mergers and acquisitions financial performance status quo and problems were discussed, trying to solve the financial integration process in question, in order to be able to provide some guidance for fiscal consolidation are in or about acquisitions of domestic pharmaceutical enterprises, improve the success rate of mergers and acquisitions.